ABSTRACT
AIMS/HYPOTHESIS: Oral administration of antigen can induce immunological tolerance. Insulin is a key autoantigen in childhood type 1 diabetes. Here, oral insulin was given as antigen-specific immunotherapy before the onset of autoimmunity in children from age 6 months to assess its safety and immune response actions on immunity and the gut microbiome. METHODS: A phase I/II randomised controlled trial was performed in a single clinical study centre in Germany. Participants were 44 islet autoantibody-negative children aged 6 months to 2.99 years who had a first-degree relative with type 1 diabetes and a susceptible HLA DR4-DQ8-containing genotype. Children were randomised 1:1 to daily oral insulin (7.5 mg with dose escalation to 67.5 mg) or placebo for 12 months using a web-based computer system. The primary outcome was immune efficacy pre-specified as induction of antibody or T cell responses to insulin and measured in a central treatment-blinded laboratory. RESULTS: Randomisation was performed in 44 children. One child in the placebo group was withdrawn after the first study visit and data from 22 insulin-treated and 21 placebo-treated children were analysed. Oral insulin was well tolerated with no changes in metabolic variables. Immune responses to insulin were observed in children who received both insulin (54.5%) and placebo (66.7%), and the trial did not demonstrate an effect on its primary outcome (p = 0.54). In exploratory analyses, there was preliminary evidence that the immune response and gut microbiome were modified by the INS genotype Among children with the type 1 diabetes-susceptible INS genotype (n = 22), antibody responses to insulin were more frequent in insulin-treated (72.7%) as compared with placebo-treated children (18.2%; p = 0.03). T cell responses to insulin were modified by treatment-independent inflammatory episodes. CONCLUSIONS/INTERPRETATION: The study demonstrated that oral insulin immunotherapy in young genetically at-risk children was safe, but was not associated with an immune response as predefined in the trial primary outcome. Exploratory analyses suggested that antibody responses to oral insulin may occur in children with a susceptible INS genotype, and that inflammatory episodes may promote the activation of insulin-responsive T cells. TRIAL REGISTRATION: Clinicaltrials.gov NCT02547519 FUNDING: The main funding source was the German Center for Diabetes Research (DZD e.V.).
Subject(s)
Diabetes Mellitus, Type 1/prevention & control , Immunotherapy/methods , Insulin/administration & dosage , Administration, Oral , Antibody Formation/drug effects , Antibody Formation/genetics , Autoantibodies/drug effects , Autoantibodies/genetics , Autoimmunity/drug effects , Child, Preschool , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 1/immunology , Family , Female , Germany , Humans , Infant , Insulin/immunology , Male , Primary Prevention/methodsABSTRACT
Antibody production by the B cell compartment is a crucial part of the adaptive immune response. Dysregulated antibody production in the form of autoantibodies can cause autoimmune disease. To date, B-cell depletion with anti-CD20 antibodies is commonly applied in autoimmunity, but pre-existing plasma cells are not eliminated in this way. Alternative ways of more selective inhibition of antibody production would add to the treatment of these autoimmune diseases. To explore novel therapeutic targets in signaling pathways essential for plasmablast formation and/or immunoglobulin production, we performed a compound screen of almost 200 protein kinase inhibitors in a robust B-cell differentiation culture system. This study yielded 35 small cell-permeable compounds with a reproducible inhibitory effect on B-cell activation and plasmablast formation, among which was the clinically applied mammalian target of rapamycin (mTOR) inhibitor rapamycin. Two additional compounds targeting the phosphoinositide 3-kinase-AKT-mTOR pathway (BKM120 and WYE-354) did not affect proliferation and plasmablast formation, but specifically reduced the immunoglobulin production. With this compound screen we successfully applied a method to investigate therapeutic targets for B-cell differentiation and identified compounds in the phosphoinositide 3-kinase-AKT-mTOR pathway that could specifically inhibit immunoglobulin production only. These drugs may well be explored to be of value in current B-cell-depleting treatment regimens in autoimmune disorders.
Subject(s)
Autoantibodies/drug effects , Lymphocyte Activation/drug effects , Plasma Cells/drug effects , Protein Kinase Inhibitors/pharmacology , TOR Serine-Threonine Kinases/antagonists & inhibitors , Aminopyridines/pharmacology , Antibody Formation/drug effects , Autoantibodies/biosynthesis , Autoimmune Diseases/immunology , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Cell Differentiation/drug effects , Drug Discovery , High-Throughput Screening Assays , Humans , Morpholines/pharmacology , Plasma Cells/immunology , Purines/pharmacology , Sirolimus/pharmacologyABSTRACT
Neuromyelitis optica (NMO) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) characterized by acute optic neuritis (ON) and transverse myelitis (TM). NMO is caused by a pathogenic serum IgG antibody against the water channel aquoporin 4 (AQP4) in the majority of patients. AQP4-antibody (AQP4-ab) presence is highly specific, and differentiates NMO from multiple sclerosis. It binds to AQP4 channels on astrocytes, triggering activation of the classical complement cascade, causing granulocyte, eosinophil, and lymphocyte infiltration, culminating in injury first to astrocyte, then oligodendrocytes followed by demyelination and neuronal loss. NMO spectrum disorder (NMOSD) has recently been defined and stratified based on AQP4-ab serology status. Most NMOSD patients experience severe relapses leading to permanent neurologic disability, making suppression of relapse frequency and severity, the primary objective in disease management. The most common treatments used for relapses are steroids and plasma exchange.Currently, long-term NMOSD relapse prevention includes off-label use of immunosuppressants, particularly rituximab. In the last 2 years however, three pivotal clinical trials have expanded the spectrum of drugs available for NMOSD patients. Phase III studies have shown significant relapse reduction compared to placebo in AQP4-ab-positive patients treated with satralizumab, an interleukin-6 receptor (IL-6R) inhibitor, inebilizumab, an antibody against CD19+ B cells; and eculizumab, an antibody blocking the C5 component of complement. In light of the new evidence on NMOSD pathophysiology and of preliminary results from ongoing trials with new drugs, we present this descriptive review, highlighting promising treatment modalities as well as auspicious preclinical and clinical studies.
Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Autoantibodies/metabolism , Immunosuppressive Agents/therapeutic use , Neuromyelitis Optica/drug therapy , Neuromyelitis Optica/metabolism , Animals , Antibodies, Monoclonal, Humanized/pharmacology , Aquaporin 4/immunology , Aquaporin 4/metabolism , Astrocytes/drug effects , Astrocytes/immunology , Astrocytes/metabolism , Autoantibodies/drug effects , Autoantibodies/immunology , Azathioprine/pharmacology , Azathioprine/therapeutic use , Clinical Trials, Phase III as Topic/methods , Humans , Immunosuppressive Agents/pharmacology , Neuromyelitis Optica/immunologyABSTRACT
Pediatric opsoclonus-myoclonussyndrome (OMS) is a rare autoimmune disorder of which 50% are associated with neuroblastoma (NB). We investigated whether surface-binding autoantibodies in OMS can enhance natural killer (NK) cell-mediated cytotoxicity in these patients. OMS immunoglobulin G (IgG) bound to NB cell lines and NK cell-mediated cytotoxicity to NB cells was enhanced after preincubation with OMS-IgG, but not IgG from NB without OMS or healthy controls. Activation of NK cells by surface-binding autoantibodies may be an additional mechanism of antitumor immunity in children with NB and OMS.
Subject(s)
Apoptosis , Autoantibodies/immunology , Immunoglobulin G/adverse effects , Killer Cells, Natural/pathology , Neuroblastoma/pathology , Opsoclonus-Myoclonus Syndrome/pathology , Autoantibodies/blood , Autoantibodies/drug effects , Child, Preschool , Female , Follow-Up Studies , Humans , Immunoglobulin G/immunology , Infant , Killer Cells, Natural/immunology , Male , Neuroblastoma/blood , Neuroblastoma/complications , Neuroblastoma/immunology , Opsoclonus-Myoclonus Syndrome/blood , Opsoclonus-Myoclonus Syndrome/complications , Opsoclonus-Myoclonus Syndrome/immunology , PrognosisABSTRACT
BACKGROUND: There is only limited clinical data on the benefit of intense immunosuppression in patients with severe interstitial pneumonia associated with autoimmune features or new-onset connective tissue disease. CASE PRESENTATION: We here report a series of three consecutive patients suffering from severe interstitial lung disease necessitating endotracheal intubation and mechanical ventilation. The first two patients fulfilled many diagnostic criteria for new-onset antisynthetase syndrome, the third patient for systemic lupus erythematosus. We decided to implement aggressive immunosuppressive strategies in these critically-ill patients including therapeutic plasma exchange, immunoadsorption, cyclophosphamide and rituximab. All three patients improved from respiratory failure, were successfully weaned from the respirator, and eventually dismissed from hospital with ongoing immunosuppressive therapy. CONCLUSION: Patients suffering from severe connective tissue disease-associated interstitial lung disease and respiratory failure may benefit from an aggressive immunosuppressive regimen and extracorporeal blood purification with rapid reduction of circulating autoantibodies. The impressive clinical responses in this small case series warrant a controlled clinical trial.
Subject(s)
Autoantibodies/drug effects , Immunosuppressive Agents/therapeutic use , Lung Diseases, Interstitial/drug therapy , Lupus Erythematosus, Systemic/drug therapy , Myositis/drug therapy , Autoantibodies/blood , Cyclophosphamide , Humans , Lung Diseases, Interstitial/immunology , Lupus Erythematosus, Systemic/immunology , Male , Middle Aged , Myositis/immunology , Rituximab , Treatment OutcomeABSTRACT
The recent approval of Immunologic checkpoint inhibitors as an effective therapeutic strategy against cancer came at the cost of toxicities mediated by an excessive activation of immune system against health tissues, including among others musculoskeletal and sicca complaints.The latter occur in the context of an entity reminiscent of Sjogren's syndrome, with distinct characteristics such as abrupt onset, male predominance, lower prevalence of autoantibodies and response to steroids.
Subject(s)
Immune Checkpoint Inhibitors/adverse effects , Ipilimumab/adverse effects , Nivolumab/adverse effects , Sjogren's Syndrome/chemically induced , Aged , Autoantibodies/blood , Autoantibodies/drug effects , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/immunology , Humans , Immune Checkpoint Inhibitors/therapeutic use , Ipilimumab/therapeutic use , Male , Neoplasms/drug therapy , Nivolumab/therapeutic use , Sjogren's Syndrome/immunologyABSTRACT
OBJECTIVES: SLE is a severe autoimmune disease characterized by autoreactive B cells and IC formation, which causes systemic inflammation. B cell-targeted therapy could be a promising treatment strategy in SLE patients; nevertheless, randomized clinical trials have not always been successful. However, some groups have demonstrated beneficial effects in severe SLE patients with off-label rituximab (RTX) with belimumab (BLM), or bortezomib (BTZ), which targeted different B cells subsets. This study assembled sera from SLE cohorts treated with RTX+BLM (n = 15), BTZ (n = 11) and RTX (n = 16) to get an in-depth insight into the immunological effects of these therapies on autoantibodies and IC formation. METHODS: Autoantibodies relevant for IC formation and the avidity of anti-dsDNA were determined by ELISA. IC-mediated inflammation was studied by complement levels and ex vivo serum-induced neutrophil extracellular trap formation. RESULTS: Reductions in autoantibodies were observed after all approaches, but the spectrum differed depending upon the treatment. Specifically, only RTX+BLM significantly decreased anti-C1q. Achieving seronegativity of ≥1 autoantibody, specifically anti-C1q, was associated with lower disease activity. In all SLE patients, the majority of anti-dsDNA autoantibodies had low avidity. RTX+BLM significantly reduced low-, medium- and high-avidity anti-dsDNA, while RTX and BTZ only significantly reduced medium avidity. IC-mediated inflammation, measured by C3 levels and neutrophil extracellular trap formation, improved after RTX+BLM and RTX but less after BTZ. CONCLUSION: This study demonstrated the impact of different B cell-targeted strategies on autoantibodies and IC formation and their potential clinical relevance in SLE.
Subject(s)
Antibodies, Monoclonal, Humanized/pharmacology , Antineoplastic Agents, Immunological/pharmacology , Antineoplastic Agents/pharmacology , Immunity, Humoral/drug effects , Lupus Erythematosus, Systemic/drug therapy , Adult , Antibodies, Monoclonal, Humanized/therapeutic use , Antigen-Antibody Complex/drug effects , Antigen-Antibody Complex/immunology , Antineoplastic Agents/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Autoantibodies/drug effects , Autoantibodies/immunology , B-Lymphocyte Subsets/drug effects , B-Lymphocytes/immunology , Bortezomib/pharmacology , Bortezomib/therapeutic use , Complement System Proteins/immunology , Drug Therapy, Combination , Extracellular Traps/drug effects , Female , Humans , Immunosuppressive Agents/pharmacology , Immunosuppressive Agents/therapeutic use , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/immunology , Male , Middle Aged , Research Design , Rituximab/pharmacology , Rituximab/therapeutic useABSTRACT
OBJECTIVE: To evaluate the safety, pharmacokinetics, pharmacodynamics, and exploratory efficacy of amiselimod, an oral selective sphingosine 1-phosphate receptor-1 modulator, in patients with systemic lupus erythematosus (SLE). METHODS: A multicenter, open-label phase Ib trial was conducted in Japan. Patients in Part 1 and Part 2-B received 0.2 mg amiselimod while those in Part 2-A received 0.4 mg amiselimod for 24 weeks. RESULTS: Seventeen subjects received 0.2 or 0.4 mg amiselimod. Amiselimod and amiselimod-P plasma concentrations increased dose-dependently. Peripheral blood lymphocyte count decreased in all patients after amiselimod treatment, with no clear dose response. There were no serious/severe adverse events (AEs) or clinically meaningful cardiac effects. Five subjects were withdrawn from amiselimod treatment following a decrease in lymphocyte count to <200/µl. Anti-double stranded-DNA antibody decreased from baseline to Week 24/end of treatment (EOT), with those in 2 subjects (22.2%) decreasing to within the normal range. Total SLE disease activity index 2000 score decreased by ≥4 at EOT in 7 of 17 subjects. CONCLUSIONS: Amiselimod was generally well tolerated. While no serious AEs or infectious AEs led to discontinuation, low lymphocyte counts of <200/µl were observed as a laboratory abnormality. Our findings suggest the potential efficacy of amiselimod for patients with SLE.Trial registration: ClinicalTrials.gov identifier: NCT02307643.
Subject(s)
Lupus Erythematosus, Systemic/drug therapy , Sphingosine-1-Phosphate Receptors/administration & dosage , Adult , Autoantibodies/drug effects , Double-Blind Method , Female , Humans , Lymphocytes/drug effects , Male , Middle Aged , Non-Randomized Controlled Trials as Topic , Propanolamines/administration & dosage , Propanolamines/adverse effects , Propanolamines/pharmacokinetics , Propanolamines/pharmacologyABSTRACT
BACKGROUND: Immunosuppressant drugs reduce proteinuria and anti-phospholipase A2 receptor autoantibodies (PLA2R-Ab) in primary membranous nephropathy (PMN) with varying success and associated toxicities. This study aimed to evaluate the effect of belimumab on proteinuria and PLA2R-Ab in participants with PMN. METHODS: In this prospective, open-label, experimental medicine study, 14 participants with PMN and persistent nephrotic-range proteinuria received up to 2 years belimumab monotherapy (10 mg/kg, every 4 weeks). Changes in proteinuria (urinary protein:creatinine ratio), PLA2R-Ab, albumin, cholesterol, B-cell subsets and pharmacokinetics were analysed during treatment and up to 6 months after treatment. RESULTS: Eleven participants completed to the primary endpoint (Week 28) and nine participants completed the study. In the intention-to-treat population population, baseline proteinuria of 724 mg/mmol [95% confidence interval (CI) 579-906] decreased to 498 mg/mmol (95% CI 383-649) and 130 mg/mmol (95% CI 54-312) at Weeks 28 and 104, respectively, with changes statistically significant from Week 36 (n = 11, P = 0.047). PLA2R-Ab decreased from 174 RU/mL (95% CI 79-384) at baseline to 46 RU/mL (95% CI 16-132) and 4 RU/mL (95% CI 2-6) at Weeks 28 and 104, respectively, becoming statistically significant by Week 12 (n = 13, P = 0.02). Nine participants achieved partial (n = 8) or complete (n = 1) remission. Participants with abnormal albumin and/or cholesterol at baseline gained normal/near normal levels by the last follow-up. Adverse events were consistent with those expected in this population. CONCLUSIONS: Belimumab treatment in participants with PMN can reduce PLA2R-Ab and subsequently proteinuria, important preludes to remission induction.
Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Autoantibodies/immunology , Glomerulonephritis, Membranous/complications , Immunosuppressive Agents/therapeutic use , Proteinuria/drug therapy , Receptors, Phospholipase A2/immunology , Adult , Aged , Autoantibodies/drug effects , Female , Glomerulonephritis, Membranous/immunology , Glomerulonephritis, Membranous/pathology , Humans , Male , Middle Aged , Prospective Studies , Proteinuria/etiology , Proteinuria/pathology , Remission Induction , Young AdultABSTRACT
Pemphigoid diseases are organ-specific autoimmune diseases of the skin and/or mucous membranes. They are caused by autoantibodies targeting adhesion molecules located at the dermal-epidermal junction. While the diagnostics of pemphigoid diseases and insights into their pathogenesis have improved significantly, the development of novel treatments that are effective and safe remains an unmet medical need. However, numerous pre-clinical studies and early clinical trials have recently been launched. This review summarizes some pathways leading to drug development in pemphigoid diseases, namely: (i) hypothesis-driven drug development; (ii) omics-based drug development; (iii) drug repurposing; (iv) screening-based drug development; and (v) drug development based on careful clinical observations. Ultimately, it is hoped that this will lead to personalized and curative treatments.
Subject(s)
Autoimmune Diseases/drug therapy , Drug Development , Pemphigoid, Bullous/drug therapy , Pemphigoid, Bullous/immunology , Protein-Tyrosine Kinases/administration & dosage , Autoantibodies/drug effects , Autoimmune Diseases/pathology , Cell Adhesion Molecules/immunology , Dimethyl Fumarate/therapeutic use , Doxycycline/therapeutic use , Epidermolysis Bullosa Acquisita/drug therapy , Epidermolysis Bullosa Acquisita/immunology , Epidermolysis Bullosa Acquisita/pathology , Female , Forecasting , Humans , Male , Molecular Targeted Therapy/methods , Pemphigoid, Bullous/pathology , Skin Diseases, Vesiculobullous/drug therapy , Skin Diseases, Vesiculobullous/immunology , Skin Diseases, Vesiculobullous/pathology , Translational Research, BiomedicalABSTRACT
Immune checkpoint inhibitors have transformed the treatment of advanced malignancy, while increasing the risk of immune-related adverse events. A 56-year-old woman who had received nivolumab for stage 4 renal cell carcinoma subsequently developed altered behaviour, memory deficits and worsening of previously stable epilepsy. MR scan of the brain showed bilateral FLAIR (fluid-attenuated inversion recovery) hyperintensity of the mesial temporal lobes, and there were anti-Ma2 antibodies in both serum and cerebrospinal fluid. She was treated with corticosteroids but developed further clinical relapses requiring immunoglobulin and rituximab. The immune-related adverse events relating to immune checkpoint inhibitors are an emerging challenge for the neurologist. Some cases are refractory and require serial immunosuppression.
Subject(s)
Antigens, Neoplasm/metabolism , Autoantibodies/metabolism , Encephalitis/drug therapy , Encephalitis/metabolism , Hashimoto Disease/drug therapy , Hashimoto Disease/metabolism , Immune Checkpoint Inhibitors/therapeutic use , Nerve Tissue Proteins/metabolism , Autoantibodies/drug effects , Encephalitis/diagnostic imaging , Female , Hashimoto Disease/diagnostic imaging , Humans , Immune Checkpoint Inhibitors/pharmacology , Middle AgedABSTRACT
Antiphospholipid syndrome, also known as 'Hughes Syndrome', is an autoimmune disease characterised by a set of clinical manifestations, almost all of which are direct or indirect sequelae of a hypercoagulable state involving the venous, and to a lesser extent the arterial vasculature. The incidence and prevalence of antiphospholipid syndrome are estimated at approximately 5 de novo cases per 100 000 per year and 40-50 cases per 100 000 individuals, respectively. The clinical spectrum of antiphospholipid syndrome involves haematological (thrombocytopaenia, venous thrombosis), obstetrical (recurrent pregnancy loss), neurological (stroke, transient ischaemic attack, migraine, seizures, cognitive dysfunction, chorea, transverse myelitis, multiple sclerosis), cardiovascular (cardiac valve disease), dermatological (livedo reticularis and racemosa, skin ulceration and necrosis), renal (glomerulonephritis, renal thrombotic microangiopathy) and orthopaedic (avascular necrosis of bones, non-traumatic fractures) manifestations, among others. In addition to the classical antiphospholipid antibodies, namely anticardiolipin antibodies and lupus anticoagulant, new autoantibodies and antibody complexes of different immunoglobulin subtypes (IgA, IgG, IgM) are now recognised as significant contributors to the pathogenesis of antiphospholipid syndrome. Anticoagulation remains the cornerstone in the management of antiphospholipid syndrome; nevertheless, new drugs and therapeutic strategies are being tested, and some have been found effective for the primary and secondary thromboprophylaxis in antiphospholipid syndrome.
Subject(s)
Anticoagulants/therapeutic use , Antiphospholipid Syndrome/drug therapy , Venous Thrombosis/prevention & control , Antiphospholipid Syndrome/immunology , Autoantibodies/drug effects , Autoantibodies/immunology , Humans , Venous Thrombosis/immunologyABSTRACT
OBJECTIVES: Sustained disease-modifying antirheumatic drug (DMARD)-free status, the sustained absence of synovitis after cessation of DMARD therapy, is infrequent in autoantibody-positive rheumatoid arthritis (RA), but approximates cure (ie, disappearance of signs and symptoms). It was recently suggested that immunological remission, defined as disappearance of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF), underlies this outcome. Therefore, this long-term observational study determined if autoantibodies disappear in RA patients who achieved sustained DMARD-free remission. METHODS: We studied 95 ACPA-positive and/or RF-positive RA patients who achieved DMARD-free remission after median 4.8 years and kept this status for the remaining follow-up (median 4.2 years). Additionally, 21 autoantibody-positive RA patients with a late flare, defined as recurrence of clinical synovitis after a DMARD-free status of ≥1 year, and 45 autoantibody-positive RA patients who were unable to stop DMARD therapy (during median 10 years) were studied. Anti-cyclic citrullinated peptide 2 (anti-CCP2) IgG, IgM and RF IgM levels were measured in 587 samples obtained at diagnosis, before and after achieving DMARD-free remission. RESULTS: 13% of anti-CCP2 IgG-positive RA patients had seroreverted when achieving remission. In RA patients with a flare and persistent disease this was 8% and 6%, respectively (p=0.63). For anti-CCP2 IgM and RF IgM, similar results were observed. Evaluating the estimated slope of serially measured levels revealed that RF levels decreased more in patients with than without remission (p<0.001); the course of anti-CCP2 levels was not different (p=0.66). CONCLUSIONS: Sustained DMARD-free status in autoantibody-positive RA was not paralleled by an increased frequency of reversion to autoantibody negativity. This form of immunological remission may therefore not be a treatment target in patients with classified RA.
Subject(s)
Anti-Citrullinated Protein Antibodies/drug effects , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Autoantibodies/drug effects , Rheumatoid Factor/drug effects , Adult , Aged , Anti-Citrullinated Protein Antibodies/blood , Arthritis, Rheumatoid/blood , Autoantibodies/blood , Female , Follow-Up Studies , Humans , Induction Chemotherapy , Longitudinal Studies , Male , Middle Aged , Rheumatoid Factor/blood , Time Factors , Treatment OutcomeABSTRACT
This paper summarizes and reviews the mechanisms of action and data concerning efficacy of recommended treatments as well as other treatments that have been tested, independently of the outcomes, in the management of chronic spontaneous urticaria. Due to the central role of mast cells, basophils and histamine in the pathophysiology of this disease, H1-antihistamines remain the first-line treatment. However, current knowledge about this complex disease, also recognizes an important role for T lymphocytes, B lymphocytes, and autoantibodies. Implications of these others mediators thus provide further targets for treatment. Indeed, agents previously used to treat other autoimmune and inflammatory diseases, have demonstrated efficacy in chronic spontaneous urticaria and are therefore potential therapeutic alternatives for antihistamine unresponsive patients.
Subject(s)
Histamine H1 Antagonists/therapeutic use , Mast Cells/drug effects , Urticaria/drug therapy , Autoantibodies/drug effects , Autoantibodies/immunology , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Basophils/drug effects , Basophils/immunology , Chronic Disease , Histamine H1 Antagonists/immunology , Humans , Mast Cells/immunology , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , Urticaria/immunology , Urticaria/pathologyABSTRACT
Rituximab is an effective therapy resulting in a platelet count improvement in 60% of patients with immune thrombocytopenia (ITP). Rituximab depletes B cells; thus, a reduction in platelet autoantibody levels would be anticipated in patients who achieve a clinical response to this treatment. The objectives of this study were to determine whether rituximab was associated with a reduction in platelet autoantibody levels, and to correlate the loss of autoantibodies with the achievement of a treatment response. We performed a case-control study nested within a previous randomized controlled trial of standard therapy plus adjuvant rituximab or placebo. We measured platelet-bound anti-glycoprotein (GP) IIbIIIa and anti-GPIbIX using the antigen capture test. Of 55 evaluable patients, 25 (45%) had a detectable platelet autoantibody at baseline. Rituximab was associated with a significant reduction in anti-GPIIbIIIa levels (P = 0·02) but not anti-GPIbIX levels (P = 0·51) compared with placebo. Neither the presence of an autoantibody at baseline nor the loss of the autoantibody after treatment was associated with a response to rituximab. The subset of patients with persistent autoantibodies after treatment failed to achieve a platelet count response, suggesting that persistence of platelet autoantibodies can be a marker of disease severity.
Subject(s)
Autoantibodies/metabolism , Blood Platelets/immunology , Immunologic Factors/therapeutic use , Purpura, Thrombocytopenic, Idiopathic/drug therapy , Rituximab/therapeutic use , Adult , Autoantibodies/drug effects , Case-Control Studies , Female , Humans , Male , Middle Aged , Platelet Glycoprotein GPIIb-IIIa Complex/immunology , Platelet Glycoprotein GPIb-IX Complex/immunology , Purpura, Thrombocytopenic, Idiopathic/immunology , Treatment OutcomeABSTRACT
Objective The treatment of refractory lupus nephritis (LN) remains challenging for clinicians because these patients either do not respond to conventional therapy or relapse during the maintenance treatment period. The aim of this study was to investigate the efficacy and safety of bortezomib combined with glucocorticoids in refractory lupus patients. Methodology Five refractory LN patients aged 21 to 43 years (four females and one male) with biopsy-proven diagnosis (four with type IV and one with type V+IV) were recruited. These patients received bortezomib therapy for four cycles (1.3 mg per square meter of body surface area as an intravenous bolus on days 1, 4, 8, and 11 of 21-day cycles) and glucocorticoids (methylprednisolone 0.5 g/d intravenously for three days, followed by prednisone 0.6 mg/kg/d orally for four weeks, with gradual tapering to 10 mg/d). Proteinuria, serum albumin and creatinine, and immunological parameters were assessed, and adverse effects were also evaluated. Results After two to four bortezomib treatment cycles, four patients achieved partial remission with decreases in SLE disease activity index scores from the range of 12-16 to that of 4-8. The patients also exhibited a decline in proteinuria and an elevation of albumin level after treatment. SCr level was decreased in three of five patients with elevated SCr at baseline. The anti-autoantibodies and complements were also improved. Adverse events were of grades 1-2 and included transient thrombocytopenia, gastrointestinal symptoms and acroesthesia. During a 6- to 24-month follow-up period, three patients achieved complete remission, and one had partial remission. However, one patient received renal replacement therapy. Conclusion Bortezomib combined with glucocorticoids reduces proteinuria, improves renal function and decreases anti-autoantibodies, with good tolerance and mild adverse events, thus representing an alternative therapy for refractory LN and warranting further study.
Subject(s)
Bortezomib/pharmacology , Drug Therapy, Combination/methods , Lupus Nephritis/drug therapy , Methylprednisolone/pharmacology , Prednisone/pharmacology , Administration, Intravenous , Adult , Antineoplastic Agents/therapeutic use , Autoantibodies/drug effects , Bortezomib/administration & dosage , Bortezomib/adverse effects , Female , Glucocorticoids/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Kidney/drug effects , Kidney/physiology , Lupus Nephritis/diagnosis , Lupus Nephritis/pathology , Male , Methylprednisolone/administration & dosage , Methylprednisolone/adverse effects , Prednisone/administration & dosage , Proteinuria/drug therapy , Remission InductionABSTRACT
OBJECTIVE: To determine the relationship between changes in antibody levels towards citrullinated peptides derived from different candidate autoantigens and therapeutic outcome in early rheumatoid arthritis (RA). METHODS: Baseline and 3-month serum samples from 316 patients with early RA enrolled in the Swedish Farmacotherapy (SWEFOT) trial were analysed for antibodies against cyclic citrullinated peptides (CCP) and citrullinated peptides derived from vimentin (cVim), fibrinogen (cFib) and α-enolase (CEP-1). At 3-month follow-up, methotrexate monotherapy-inadequate responders were randomised to add-on therapy with sulfasalazine and hydroxychloroquine or infliximab. In these patients, anticitrullinated peptide antibodies (ACPA) were also assessed at 12 and 24â months. The proportion of antibody-positive patients and relative changes in antibody levels were compared across ACPA specificities and related to therapeutic response and radiographic progression. RESULTS: During the 2-year follow-up, the proportion of patients testing positive declined significantly regarding antibodies to cVim, cFib and CEP-1, while anti-CCP antibody occurrence remained stable over time. Turning anti-cVim antibody negative was most common, and anti-cVim antibody seroreversion during the first threeâ months associated with significantly less 2-year radiographic progression compared with patients who remained positive. Median antibody levels of all tested ACPAs declined uniformly during initial methotrexate therapy and following response to add-on therapy, with no significant relation to treatment regimen or radiographic progression. CONCLUSIONS: The influence of early antirheumatic therapy on ACPA seroreversions was markedly different across specificities, and early disappearance of anti-cVim antibodies associated with better radiological outcome. Thus, these data suggest that the disappearance of particular ACPA reactivities may be beneficial in early RA. TRIAL REGISTRATION NUMBER: WHO database at the Karolinska institute: CT20080004; and clinicaltrials.gov: NCT00764725.
Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/immunology , Autoantibodies/blood , Methotrexate/therapeutic use , Peptides, Cyclic/immunology , Antibody Specificity , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/diagnostic imaging , Autoantibodies/drug effects , Disease Progression , Drug Therapy, Combination , Female , Fibrinogen/immunology , Humans , Hydroxychloroquine/therapeutic use , Infliximab/therapeutic use , Male , Middle Aged , Phosphopyruvate Hydratase/immunology , Radiography , Sulfasalazine/therapeutic use , Sweden , Vimentin/immunologyABSTRACT
Bortezomib is a potent inhibitor of proteasomes currently used to eliminate malignant plasma cells in multiple myeloma patients. It is also effective in depleting both alloreactive plasma cells in acute Ab-mediated transplant rejection and their autoreactive counterparts in animal models of lupus and myasthenia gravis (MG). In this study, we demonstrate that bortezomib at 10 nM or higher concentrations killed long-lived plasma cells in cultured thymus cells from nine early-onset MG patients and consistently halted their spontaneous production not only of autoantibodies against the acetylcholine receptor but also of total IgG. Surprisingly, lenalidomide and dexamethasone had little effect on plasma cells. After bortezomib treatment, they showed ultrastructural changes characteristic of endoplasmic reticulum stress after 8 h and were no longer detectable at 24 h. Bortezomib therefore appears promising for treating MG and possibly other Ab-mediated autoimmune or allergic disorders, especially when given in short courses at modest doses before the standard immunosuppressive drugs have taken effect.
Subject(s)
Autoantibodies/metabolism , Boronic Acids/pharmacology , Plasma Cells/immunology , Proteasome Endopeptidase Complex/immunology , Proteasome Endopeptidase Complex/metabolism , Pyrazines/pharmacology , Thymus Gland/immunology , Adolescent , Adult , Age of Onset , Antineoplastic Agents/pharmacology , Autoantibodies/biosynthesis , Autoantibodies/drug effects , Bortezomib , Cells, Cultured , Endoplasmic Reticulum Stress/drug effects , Endoplasmic Reticulum Stress/immunology , Female , Humans , Male , Plasma Cells/drug effects , Plasma Cells/ultrastructure , Primary Cell Culture , Proteasome Endopeptidase Complex/drug effects , Thymus Gland/drug effects , Thymus Gland/ultrastructure , Young AdultSubject(s)
Autoantibodies/drug effects , Lupus Nephritis/immunology , Nephritis, Interstitial/immunology , Vimentin/antagonists & inhibitors , Vimentin/metabolism , Adult , Aged , Aged, 80 and over , Autoantibodies/immunology , Cross-Sectional Studies , Drug Resistance/immunology , Enzyme Inhibitors/therapeutic use , Female , Humans , Immunoglobulin Isotypes/metabolism , Immunologic Factors/pharmacology , Immunologic Factors/therapeutic use , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/immunology , Lupus Nephritis/complications , Lupus Nephritis/drug therapy , Lupus Nephritis/ethnology , Male , Middle Aged , Mycophenolic Acid/pharmacology , Mycophenolic Acid/therapeutic use , Prognosis , Rituximab/pharmacology , Rituximab/therapeutic use , Vimentin/bloodABSTRACT
PURPOSE OF REVIEW: The cause of primary ovarian insufficiency (POI) is multifactorial. Known causes include external factors such as chemotherapy, radiotherapy, exposure to endocrine-disrupting chemicals, infections that lead to a permanent insult to the ovary, autoimmune conditions, and genetic causes. An association between the quadrivalent antihuman papilloma vaccine (HPV4) and POI was recently suggested. RECENT FINDINGS: An increasing number of cases of POI post-HPV4 are being reported. Possible mechanisms for the suspected effect of HPV on female reproductive function are a toxic effect or an autoimmune response. The trigger could be the vaccine immunogen contents or the adjuvants, the latter are used to increase the immune reaction. The adjuvant in HPV4 contains aluminum. Animal models have shown aluminum exposure to inhibit expression of female reproductive hormones and to induce histologic changes in the ovaries. Specific genetic compositions may be more susceptible to developing an autoinflammatory syndrome after exposure to an environmental factor. SUMMARY: The mechanisms responsible for POI are not yet fully understood. Although case reports cannot establish causation, awareness of a possible link between HPV4 and POI will help to identify and manage future cases that may arise.